Disc Medicine, Inc. (IRON): restructuring charge — Disc Medicine cuts 20% of workforce after FDA complete response letter for bitopertin

Disc Medicine, Inc.

Restructuring plan approved Feb 26, 2026, reducing workforce by ~20%.
FDA issued complete response letter Feb 13, 2026 for bitopertin NDA in erythropoietic protoporphyria and X-linked protoporphyria.
Expected aggregate charges of ~$2.0 million, primarily severance, recorded in Q1 2026.
Implementation expected to be completed in Q2 2026; reductions focused on commercial and support functions.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Disc Medicine, Inc. announced a restructuring with charges of approximately $2.0 million affecting commercial functions and certain supporting functions (approximately 20%).

Type: restructuring
Charge: approximately $2.0 million
Affected area: commercial functions and certain supporting functions
Headcount: approximately 20%

Exact text from the filing

Company expects to complete the implementation of the Restructuring Plan in the second quarter of 2026. The Company expects that it will incur aggregate charges of approximately $2.0 million in connection with the Restructuring Plan, consisting primarily of severance costs, which will be recorded primarily in the first quarter of 2026. The costs that the Company

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-082855

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.